Ask AI
Bill116th CongressFiled Oct 28, 2019Health
H.R. 4866

National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2020

Bill journey · stage 2 of 5

Under committee review

Filed
Comm.
Floor
Both
Law

What it doesSummary passed house (Sep 21, 2020)

National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2020

This bill directs the Food and Drug Administration (FDA) to designate qualified institutions of higher education as National Centers of Excellence in Continuous Pharmaceutical Manufacturing and to provide grants to the centers. Each designated center must conduct research on continuous manufacturing technologies and must share information from such research with the FDA. (Currently, most drug production involves batch manufacturing, which typically takes longer than continuous manufacturing processes.)

What just happenedSep 22, 2020

Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Who’s behind it

Rep. Pallone, Frank, Jr. [D-NJ-6](D-NJ)Sponsor
2 cosponsors1 D1 R
Read on Congress.gov
2cosponsors2committees18actions3related bills12subjects
  1. Sep 22, 2020IntroReferral

    Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

    Health, Education, Labor, and Pensions Committee
  2. Sep 21, 2020FloorH38310

    Motion to reconsider laid on the table Agreed to without objection.

  3. Sep 21, 2020FloorH37300

    On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4616-4617)

  4. Sep 21, 2020Floor8000

    Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.

  5. Sep 21, 2020FloorH8D000

    DEBATE - The House proceeded with forty minutes of debate on H.R. 4866.

  6. Sep 21, 2020FloorH30000

    Considered under suspension of the rules. (consideration: CR H4616-4618)

  7. Sep 21, 2020FloorH30300

    Mrs. Dingell moved to suspend the rules and pass the bill, as amended.

  8. Sep 17, 2020CalendarsH12410

    Placed on the Union Calendar, Calendar No. 413.

  9. Sep 17, 2020CommitteeH12200

    Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 116-513.

    Energy and Commerce Committee
  10. Sep 17, 2020Committee5000

    Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 116-513.

    Energy and Commerce Committee
  11. Jul 15, 2020Committee

    Ordered to be Reported (Amended) by Voice Vote.

    Energy and Commerce Committee
  12. Jul 15, 2020Committee

    Committee Consideration and Mark-up Session Held.

    Energy and Commerce Committee
  13. Mar 11, 2020Committee

    Forwarded by Subcommittee to Full Committee (Amended) by Voice Vote .

    Health Subcommittee
  14. Mar 11, 2020Committee

    Subcommittee Consideration and Mark-up Session Held.

    Health Subcommittee
  15. Oct 29, 2019Committee

    Referred to the Subcommittee on Health.

    Health Subcommittee
  16. Oct 28, 2019IntroReferralH11100

    Referred to the House Committee on Energy and Commerce.

    Energy and Commerce Committee
  17. Oct 28, 2019IntroReferralIntro-H

    Introduced in House

  18. Oct 28, 2019IntroReferral1000

    Introduced in House

Passed HouseSep 21, 202053

National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2020

This bill directs the Food and Drug Administration (FDA) to designate qualified institutions of higher education as National Centers of Excellence in Continuous Pharmaceutical Manufacturing and to provide grants to the centers. Each designated center must conduct research on continuous manufacturing technologies and must share information from such research with the FDA. (Currently, most drug production involves batch manufacturing, which typically takes longer than continuous manufacturing processes.)

Introduced in HouseOct 28, 2019

National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2019

This bill directs the Food and Drug Administration (FDA) to designate qualified institutions of higher education as National Centers of Excellence in Continuous Pharmaceutical Manufacturing and to provide grants to the centers. Each designated center must conduct research on continuous manufacturing technologies and must share information from such research with the FDA. (Currently, most drug production involves batch manufacturing, which typically takes longer than continuous manufacturing processes.)

National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2020 — Informed